S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55

Nature's Sunshine Products Stock Forecast, Price & News

-0.64 (-3.44%)
(As of 01/18/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
85,583 shs
Average Volume
59,626 shs
Market Capitalization
$355.11 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NATR News and Ratings via Email

Sign-up to receive the latest news and ratings for Nature's Sunshine Products and its competitors with MarketBeat's FREE daily newsletter.


About Nature's Sunshine Products

Natures Sunshine Products, Inc. engages in the manufacturing and direct selling of nutritional and personal care products. Its product lines include general health, immune, cardiovascular, digestive, personal care, and weight management. It operates through the following geographical segments: Asia, Europe, North America, and Latin America and Other. The company was founded by Eugene L. Hughes, Kristine F. Hughes, and Pauline Hughes-Francis in 1972 and is headquartered in Lehi, UT.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Personal Products
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$385.20 million
Cash Flow
$1.57 per share
Book Value
$8.00 per share


Net Income
$21.34 million
Pretax Margin




Free Float
Market Cap
$355.11 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.98 out of 5 stars

Medical Sector

639th out of 1,414 stocks

Pharmaceutical Preparations Industry

310th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Nature's Sunshine Products (NASDAQ:NATR) Frequently Asked Questions

Is Nature's Sunshine Products a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nature's Sunshine Products in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Nature's Sunshine Products stock.
View analyst ratings for Nature's Sunshine Products
or view top-rated stocks.

How has Nature's Sunshine Products' stock price been impacted by Coronavirus (COVID-19)?

Nature's Sunshine Products' stock was trading at $7.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NATR shares have increased by 130.7% and is now trading at $17.97.
View which stocks have been most impacted by COVID-19

Are investors shorting Nature's Sunshine Products?

Nature's Sunshine Products saw a decrease in short interest in the month of December. As of December 15th, there was short interest totaling 49,300 shares, a decrease of 20.6% from the November 30th total of 62,100 shares. Based on an average daily volume of 78,800 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.3% of the company's shares are short sold.
View Nature's Sunshine Products' Short Interest

When is Nature's Sunshine Products' next earnings date?

Nature's Sunshine Products is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Nature's Sunshine Products

How were Nature's Sunshine Products' earnings last quarter?

Nature's Sunshine Products, Inc. (NASDAQ:NATR) released its earnings results on Thursday, November, 4th. The company reported $0.21 earnings per share (EPS) for the quarter. The business had revenue of $114.75 million for the quarter. Nature's Sunshine Products had a trailing twelve-month return on equity of 14.29% and a net margin of 4.97%.
View Nature's Sunshine Products' earnings history

How often does Nature's Sunshine Products pay dividends? What is the dividend yield for Nature's Sunshine Products?

Nature's Sunshine Products announced a dividend on Wednesday, March 10th. Stockholders of record on Monday, March 29th will be given a dividend of $1.00 per share on Friday, April 9th. The ex-dividend date of this dividend is Friday, March 26th.
View Nature's Sunshine Products' dividend history

What price target have analysts set for NATR?

1 Wall Street analysts have issued 12 month price targets for Nature's Sunshine Products' shares. Their forecasts range from $24.00 to $24.00. On average, they expect Nature's Sunshine Products' stock price to reach $24.00 in the next year. This suggests a possible upside of 33.6% from the stock's current price.
View analysts' price targets for Nature's Sunshine Products
or view top-rated stocks among Wall Street analysts.

Who are Nature's Sunshine Products' key executives?

Nature's Sunshine Products' management team includes the following people:
  • Terrence O. Moorehead, President, Chief Executive Officer & Director
  • Joseph W. Baty, Chief Financial Officer, Treasurer & EVP-Finance
  • Eddie Silcock, President-North America & Executive Vice President
  • Bryant J. Yates, Executive Vice President & President-Europe
  • Nathan G. Brower, Secretary, Executive VP & General Counsel

What is Terrence Moorehead's approval rating as Nature's Sunshine Products' CEO?

13 employees have rated Nature's Sunshine Products CEO Terrence Moorehead on Glassdoor.com. Terrence Moorehead has an approval rating of 86% among Nature's Sunshine Products' employees.

Who are some of Nature's Sunshine Products' key competitors?

What other stocks do shareholders of Nature's Sunshine Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nature's Sunshine Products investors own include Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), AbbVie (ABBV), Akorn (AKRX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Global Blood Therapeutics (GBT).

What is Nature's Sunshine Products' stock symbol?

Nature's Sunshine Products trades on the NASDAQ under the ticker symbol "NATR."

Who are Nature's Sunshine Products' major shareholders?

Nature's Sunshine Products' stock is owned by many different institutional and retail investors. Top institutional investors include Procyon Private Wealth Partners LLC (0.21%). Company insiders that own Nature's Sunshine Products stock include Prescott Group Capital Managem and Wynnefield Partners Small Cap.
View institutional ownership trends for Nature's Sunshine Products

Which institutional investors are buying Nature's Sunshine Products stock?

NATR stock was purchased by a variety of institutional investors in the last quarter, including Procyon Private Wealth Partners LLC.
View insider buying and selling activity for Nature's Sunshine Products
or or view top insider-buying stocks.

How do I buy shares of Nature's Sunshine Products?

Shares of NATR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nature's Sunshine Products' stock price today?

One share of NATR stock can currently be purchased for approximately $17.97.

How much money does Nature's Sunshine Products make?

Nature's Sunshine Products has a market capitalization of $355.11 million and generates $385.20 million in revenue each year. The company earns $21.34 million in net income (profit) each year or $1.05 on an earnings per share basis.

How many employees does Nature's Sunshine Products have?

Nature's Sunshine Products employs 837 workers across the globe.

What is Nature's Sunshine Products' official website?

The official website for Nature's Sunshine Products is www.naturessunshine.com.

Where are Nature's Sunshine Products' headquarters?

Nature's Sunshine Products is headquartered at 2901 WEST BLUEGRASS BOULEVARD SUITE 100, LEHI UT, 84043.

How can I contact Nature's Sunshine Products?

Nature's Sunshine Products' mailing address is 2901 WEST BLUEGRASS BOULEVARD SUITE 100, LEHI UT, 84043. The company can be reached via phone at (801) 341-7900, via email at [email protected], or via fax at 801-342-4305.

This page was last updated on 1/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.